Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.

Mathieu Anheim 1, 2, 3 Ben Monga 1, 4 Marie Fleury 2 P. Charles 3 Clara Barbot 5, 6 M. Salih 7 Jean-Pierre Delaunoy 8 M. Fritsch 8 Larissa Arning 9 Matthis Synofzik 10 Ludger Schöls 10 Jorge Sequeiros 11 Cyril Goizet 12 Cécilia Marelli 3 Isabelle Le Ber 3, 13 Jeannette Koht 3, 13, 14 José Gazulla 15 Jan De Bleecker 16 Mawia Mukhtar 17 Nadège Drouot 1 Lamia Ali-Pacha 18 Traki Benhassine 19 Mohammed Chbicheb 20 A. M'Zahem 21 A. Hamri 21 Brigitte Chabrol 22 Jean Pouget 23 R. Murphy 24 M. Watanabe 25 P. Coutinho 26 M. Tazir 18 Alexandra Durr 3, 13 Alexis Brice 3, 13 Christine Tranchant 1, 2 Michel Koenig 1, 8
Abstract : Ataxia with oculomotor apraxia type 2 (AOA2) is an autosomal recessive disease due to mutations in the senataxin gene, causing progressive cerebellar ataxia with peripheral neuropathy, cerebellar atrophy, occasional oculomotor apraxia and elevated alpha-feto-protein (AFP) serum level. We compiled a series of 67 previously reported and 58 novel ataxic patients who underwent senataxin gene sequencing because of suspected AOA2. An AOA2 diagnosis was established for 90 patients, originating from 15 countries worldwide, and 25 new senataxin gene mutations were found. In patients with AOA2, median AFP serum level was 31.0 microg/l at diagnosis, which was higher than the median AFP level of AOA2 negative patients: 13.8 microg/l, P = 0.0004; itself higher than the normal level (3.4 microg/l, range from 0.5 to 17.2 microg/l) because elevated AFP was one of the possible selection criteria. Polyneuropathy was found in 97.5% of AOA2 patients, cerebellar atrophy in 96%, occasional oculomotor apraxia in 51%, pyramidal signs in 20.5%, head tremor in 14%, dystonia in 13.5%, strabismus in 12.3% and chorea in 9.5%. No patient was lacking both peripheral neuropathy and cerebellar atrophy. The age at onset and presence of occasional oculomotor apraxia were negatively correlated to the progression rate of the disease (P = 0.03 and P = 0.009, respectively), whereas strabismus was positively correlated to the progression rate (P = 0.03). An increased AFP level as well as cerebellar atrophy seem to be stable in the course of the disease and to occur mostly at or before the onset of the disease. One of the two patients with a normal AFP level at diagnosis had high AFP levels 4 years later, while the other had borderline levels. The probability of missing AOA2 diagnosis, in case of sequencing senataxin gene only in non-Friedreich ataxia non-ataxia-telangiectasia ataxic patients with AFP level > or =7 microg/l, is 0.23% and the probability for a non-Friedreich ataxia non-ataxia-telangiectasia ataxic patient to be affected with AOA2 with AFP levels > or =7 microg/l is 46%. Therefore, selection of patients with an AFP level above 7 microg/l for senataxin gene sequencing is a good strategy for AOA2 diagnosis. Pyramidal signs and dystonia were more frequent and disease was less severe with missense mutations in the helicase domain of senataxin gene than with missense mutations out of helicase domain and deletion and nonsense mutations (P = 0.001, P = 0.008 and P = 0.01, respectively). The lack of pyramidal signs in most patients may be explained by masking due to severe motor neuropathy.
Type de document :
Article dans une revue
Brain - A Journal of Neurology , Oxford University Press (OUP), 2009, 132 (Pt 10), pp.2688-98. 〈10.1093/brain/awp211〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00437772
Contributeur : Maité Peney <>
Soumis le : mardi 1 décembre 2009 - 14:09:35
Dernière modification le : vendredi 13 juillet 2018 - 13:26:05

Lien texte intégral

Identifiants

Collections

Citation

Mathieu Anheim, Ben Monga, Marie Fleury, P. Charles, Clara Barbot, et al.. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.. Brain - A Journal of Neurology , Oxford University Press (OUP), 2009, 132 (Pt 10), pp.2688-98. 〈10.1093/brain/awp211〉. 〈inserm-00437772〉

Partager

Métriques

Consultations de la notice

1484